• Publications
  • Influence
Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia
The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.
Acute nonspecific (musculoskeletal) low back pain Guidelines of the Russian Society for the Study of Pain (RSSP)
A patient with acute nonspecific (musculoskeletal) LBP should be informed about the favorable outcome of the disease and the need to maintain physical and social activities, to avoid bed rest, and, if possible, to continue professional activities.
Chronic Musculoskeletal Pain Associated with a Previous SARS-CoV-2 Infection
COVID-19-induced damage to the musculoskeletal and nervous systems can contribute to the exacerbation of diseases characterised by chronic pain, and chronic pain is one of PCS manifestations that requires special attention, timely diagnosis, and comprehensive individual therapy.
Comorbidities in clinical practice. Algorithms for diagnostics and treatment
There is no clear data indicating the risk of specific complications when using non-steroidal anti-inflammatory drugs (NSAIDs), and in particular ibuprofen, for COVID-19 infection, but when using NSAIDs in patients with acute respiratory viral diseases, keep in mind the possibility of class-specific complications from the gastrointestinal tract, cardiovascular system and kidneys.
“Post-COVID syndrome”: The focus is on musculoskeletal pain
The main elements of PCS are chronic pain, fatigue, and psychoemotional problems, which can cause the development and exacerbation of diseases characterized by chronic pain and fatigue, such as fibromyalgia and chronic fatigue syndrome.
[The efficacy of meloxicam in acute back pain: results of an observational non-interventional multicenter study].
Meloxicam in a dose of 15 mg/day is an effective and safe therapy for the treatment of acute NSBP and the analgesic effect of NSAIDs is higher in young patients, patients with the first episode of NBC and a good response to NSAIDs in history.
Chronic pain and central sensitization in immuno-inflammatory rheumatic diseases: pathogenesis, clinical manifestations, the possibility of using targeted disease modifying antirheumatic drugs
JAK inhibitors, such as tofacitinib, used in RA and PsA, can also be considered as an effective means of controlling chronic pain in these diseases.
[Control of pain in the early post-traumatic period in the outpatient practice. Results of the multi-center observational study RAPTOR (Rational Analgesia PostTraumatic: an Observational Research)].
PTP decreases rapidly in most patients after a radius fracture, injury of the knee, and ankle ligament injury while taking the original meloxicam, however, in a significant part of patients, moderate or severe PTP persists after 48 weeks, which requires prolonged analgesic therapy and active rehabilitation.
Evaluation of the population safety of nonsteroidal anti-inflammatory drugs in the framework of the Pan-European SOS program: focus on aceclofenac
Analysis of national databases in the Netherlands, Italy, Germany, and the UK has indicated that aceclofenac does not increase the risk of hospitalization for heart failure, and is characterized by a very low risk of gastrointestinal and cardiovascular events.